博瑞医药：股票交易严重异常波动 公司不存在应披露而未披露的重大事项

Core Viewpoint - 博瑞医药's stock has experienced significant volatility, with a cumulative decline of 50% over the last 10 trading days, prompting the company to issue a notice regarding the abnormal trading activity [1] Company Summary - 博瑞医药 confirmed through self-inspection and communication with its controlling shareholder that there are no undisclosed significant matters as of the announcement date [1] - As of October 9, 2025, 博瑞医药's closing price was 57.57 yuan per share [1] - The company's latest rolling price-to-earnings (P/E) ratio is 243.45, significantly higher than the average rolling P/E ratio of 30.82 for the pharmaceutical manufacturing industry over the past month [1] Industry Summary - The pharmaceutical manufacturing industry has an average rolling P/E ratio of 30.82, indicating a substantial valuation disparity between 博瑞医药 and its industry peers [1]